I diopathic pulmonary arterial hypertension (IPAH) is an uncommon disease with a poor prognosis. Its incidence is 1 to 2 cases per million, and median survival after diagnosis is ≈2.8 years. 1, 2 Since the early prospective IPAH registry data were published, medical therapy has advanced with the advent of prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors. 3 A contemporary metaanalysis of randomized, controlled trials associated these therapies with a 43% relative reduction in early mortality compared with placebo (3.8% versus 1.5% at 100 days). 4 The recent subanalysis of IPAH patient data from the REVEAL registry (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) corroborates the improved outcomes noted in randomized trials, showing 93% 1-year survival. 5,6 However, for medically refractory IPAH, lung and heart-lung transplantation remain indispensable therapies. 7, 8 
shorter ischemic and cardiopulmonary bypass times, SLT was initially the favored treatment for IPAH; single-center studies demonstrated early SLT outcomes equivalent to those of DLT in IPAH patients with normal right-heart function. [9] [10] [11] In contrast, recent International Society of Heart and Lung Transplantation registry data associate DLT with better longterm outcomes than SLT, although these data are not limited to IPAH patients. 12 The suggestion that DLT improves late outcomes, along with the problem of recurrent pulmonary hypertension in SLT recipients with IPAH, has caused most institutions to favor DLT or HLT over SLT for IPAH. [13] [14] [15] Outcomes have been largely equivalent between HLT and DLT recipients with IPAH despite HLT recipients' worse preoperative cardiac function, higher wedge pressures, and poorer functional status. [14] [15] [16] [17] The International Society of Heart and Lung Transplantation registry data from 1990 to 2008 show a median survival of 4.9 years after lung transplantation (LUT) and 5.0 years after HLT in IPAH patients. 12 The majority of posttransplantation deaths in IPAH patients transpire in the first year; among patients who survive that first year, the median conditional survival is an impressive 9.3 years with LUT and 10.1 years with HLT. 12 Auspiciously, International Society of Heart and Lung Transplantation survival statistics for patients who received LUT or HLT since 2000 show a dramatic improvement compared with historical data; median survival is 5.7 years for LUT recipients and 6.3 years for HLT recipients. 12 The implementation of the lung allocation score (LAS) algorithm represented a dramatic shift in organ allocation methodology from an accumulated wait-list time algorithm to an allocation scheme based on preoperative characteristics associated with both high wait-list mortality risk and good posttransplantation outcomes. 18 Pulmonary arterial hypertension patients (including IPAH patients) in the LAS era appear to receive low LAS values, resulting in a lower incidence of transplantation and a higher incidence of death while waitlisted compared with other patients listed for transplantation. 19 We reviewed the United Network for Organ Sharing (UNOS) database and compared wait-list and posttransplantation outcomes between the pre-and post-LAS eras for patients with IPAH who were listed for LUT or HLT.
Methods

Data Collection and Study Population
We retrospectively reviewed data from UNOS's Standard Transplant Analysis and Research files. Our institutional research board granted the study an exemption because the data were deidentified. We identified 28 183 patients listed for LUT or HLT between September 1, 1998 , and December 31, 2011 (≈80 months before and after the LAS matching algorithm was implemented on May 4, 2005) . Of these patients, 1739 were identified as having IPAH as their primary diagnosis. We excluded 309 of them because they were <18 years old to avoid including patients with congenital heart disease mistakenly identified as having IPAH as their primary diagnosis. We grouped the remaining 1430 patients by organ listed and LAS era: 667 and 548 patients were listed for LUT and 101 and 114 patients for HLT in the pre-and post-LAS eras, respectively. There was some era crossover, in which patients initially listed in the pre-LAS era did not receive a transplant during that era and were relisted in the post-LAS era. These era-crossover patients (n=182, of whom 38 received transplants in the post-LAS era) were included in the post-LAS cohort (modeling them from the time of relisting in the post-LAS era). Sensitivity analysis showed that excluding the era-crossover patients did not significantly affect our results; thus, these patients were included in the present study. Patients listed in the pre-LAS era who did not undergo transplantation before May 4, 2005 , and who were never relisted in the post-LAS era were censored at the start of that era.
We also identified 17 867 patients who underwent LUT or HLT during the study period. Among these patients, IPAH was the primary diagnosis of 712; we excluded 102 of these patients because they were <18 years old. The 21 patients who underwent SLT were not analyzed primarily but were included in our regression analyses because of their scarcity. We divided the remaining 589 patients by both organ received and LAS era: 225 and 223 patients underwent DLT and 66 and 75 patients underwent HLT in the pre-and post-LAS eras, respectively.
Primary End Points
The primary end point for wait-listed patients was a composite of death on the wait list or removal from the list because of clinical deterioration (ie, becoming too sick to receive a transplant). The cumulative incidence of transplantation among wait-listed patients was analyzed secondarily. Patients removed from the list because of recovery or for other reasons (<5% of the overall cohort) were censored at the time of removal. The primary end point for the transplant recipients was posttransplantation death.
Institutional Volume
Institutional volume during the study period was examined to assess its effect on wait-list and posttransplantation outcomes. For LUT candidates, a listing institution was defined as medium or high volume if it wait-listed ≥500 LUT candidates, and a transplant institution was defined as medium or high volume if it performed ≥250 LUTs. For HLT candidates, a listing institution was defined as medium or high volume if it wait-listed ≥50 HLT candidates, and a transplant institution was defined as medium or high volume if it performed ≥10 HLTs.
Statistical Analysis
Demographics and clinical status at listing and transplantation were compared by LAS era for LUT and HLT candidates by use of 2-sample t tests for continuous variables and χ 2 or Fisher exact tests for categorical variables. Our 4 main analyses examined the incidence of transplantation and mortality in LUT-listed and HLT-listed patients in the pre-and post-LAS eras and posttransplantation survival in LUT and HLT recipients in both eras.
Missing values were imputed to avoid case deletion in our multivariable and propensity-matching analyses. 20, 21 Two separate multiple imputations were performed (1 for variables at listing, 1 for variables at transplantation) with a Markov chain Monte Carlo method that assumed a multivariate normal distribution of our data (20 imputations were performed because of our large sample and moderate amount of missing data [<30%]). 22, 23 The complete sets of observed values (at listing [ Table 1 ] or at transplantation [ Table 2 ]) were used as covariates for prediction purposes. 24 Differences in patient variables between groups were controlled for with propensity-score matching. 25 Multivariable logistic regression models that included all available prelisting or pretransplantation variables were used to develop a propensity score for all patients in each of the 4 previously described analyses; to handle missing data, propensity scores were calculated across all imputed data sets using the across approach described by Mitra. 20, 26 We next performed a 1:1 nearest-neighbor matching algorithm without replacement (using a caliper of 0.25 of the standard deviation of the linear propensity score); balance was achieved in our model by the standardized differences approach. 20, 27, 28 Semiparametric estimation of cumulative incidence functions (competing outcomes analysis) was performed to assess the incidences of transplantation and mortality for wait-listed patients. 29 The Pepe and Mori test statistic was used to compare cumulative incidence by guest on April 23, 2017 http://circ.ahajournals.org/ Downloaded from functions. 30 Posttransplantation survival distributions were estimated with the nonparametric Kaplan-Meier method. 31 The Wilcoxon test was used to compare these distributions because it is sensitive to early differences and because our long-term follow-up of post-LAS era patients was limited by their recent transplantation dates. 32 These comparisons of wait-list and posttransplantation outcomes were performed for the 4 original unmatched groups and repeated in our 4 propensity-matched groups.
Univariate and multivariable time-varying Cox proportional hazards regression analyses assessed the effect of listing characteristics and the time-varying variables of SLT, DLT, and HLT on mortality from the time of listing. 33 20) . Potential interactions between covariates were tested. The Akaike information criterion, likelihood ratio test, and area under the receiver operating curve were applied to ensure that we included all variables that significantly affected our model's explanatory power. Nonsignificant variables were retained in our final multivariable models if they were plausible predictors of survival, unless they overly decreased the variance of our predictive values (ie, had an untoward bias-variance tradeoff). The final model included the following variables: Age, sex, race, education, insurance status, institution volume, LAS era, body mass index, New York Heart Association functional class, life support requirement, cardiac index, mean pulmonary artery pressure, pulmonary capillary wedge pressure, forced vital capacity, oxygen requirement at rest, creatinine clearance, diabetes mellitus, and whether the patient was listed for HLT, underwent SLT, underwent DLT, or underwent HLT. A second Cox proportional hazards regression analysis (not time-varying) was constructed in the same manner to assess the effects of pretransplantation characteristics on posttransplantation mortality. This model included the following variables: Age, sex, race, insurance status, institutional volume, post-LAS era, body mass index, life support requirement, donor age, and donor/recipient sex match. Means are presented with SDs, and hazard ratios are presented with 95% confidence intervals. All probability values are 2-sided, and P<0.05 was considered significant. Because the present study was exploratory, no adjustments were made for multiple comparisons. 35 Analyses were conducted with STATA software (version 12, StataCorp LP, College Station, TX).
Results
Patient Characteristics at Time of Listing
At the time of listing, patients listed in the post-LAS era had worse comorbidities than their pre-LAS counterparts ( Table 1) . With propensity-matching, subgroups from the preand post-LAS eras were selected for our LUT-listed and HLTlisted comparisons. No differences in listing characteristics were noted in our propensity-matched subgroups ( Table I in 
Patient Characteristics at Time of Transplantation
Post-LAS era organ recipients had worse comorbidities than their pre-LAS counterparts at the time of transplantation ( Table 2) . With propensity matching, subgroups from the preand post-LAS eras were selected for our DLT-recipient and HLT-recipient comparisons. No differences in listing characteristics were noted in our propensity-matched pre-and post-LAS era DLT patients, whereas only the prevalence of college education and diabetes mellitus remained dissimilar between the propensity-matched pre-and post-LAS HLT recipients ( Table II in 
Wait-List Incidence of Transplantation and Mortality
Competing outcomes analysis of the cumulative incidence of mortality and transplantation on the wait list for LUT-listed IPAH patients ( Figure 1A) showed that the incidence of transplantation was higher in the post-LAS era than in the pre-LAS era (39% versus 18% at 2 years, respectively; P<0.001), whereas the incidence of death on the wait list was lower (23% versus 31% at 2 years, respectively; P=0.05). These results were substantiated in the propensity-matched comparison ( Figure 1B ): More post-LAS patients received LUT (38% versus 17% at 2 years, respectively; P<0.001), and fewer post-LAS patients died on the LUT wait list (21% versus 33% at 2 years, respectively; P<0.001).
Among the HLT-listed IPAH patients (Figure 2A ), the incidence of transplantation was higher in the post-LAS era than in the pre-LAS era (58% versus 31% at 2 years, respectively; P=0.007), whereas the incidence of death on the wait list was lower in the post-LAS era (26% versus 39% at 2 years, respectively; P=0.04). These results were substantiated in the propensity-matched comparison ( Figure 2B ): More post-LAS patients received HLT (61% versus 41% at 2 years, respectively; P=0.009), and fewer post-LAS patients died on the HLT wait list (21% versus 34% at 2 years, respectively; P=0.006).
Posttransplantation Survival
Our assessment of post-LUT survival was limited to DLT recipients because few IPAH patients underwent SLT during the study period (n=21). Kaplan-Meier estimates of survival in all IPAH patients who underwent DLT ( Figure 3A ) showed greater survival in the post-LAS era than in the pre-LAS era (77% versus 65% at 2 years, respectively; P=0.04). This finding was substantiated in the propensity-matched comparison ( Figure 3B ; 80% versus 65% at 2 years, respectively; P=0.01).
Overall posttransplantation survival in HLT recipients did not improve in the post-LAS era. Kaplan-Meier estimates of survival for all IPAH patients who underwent HLT in the pre-LAS and post-LAS eras ( Figure 4A ; 74% versus 73% at 2 years, respectively; P=0.52) revealed a nonsignificant early survival benefit in post-LAS patients but equivalent late survival in both eras. Likewise, among the propensity-matched patients, there was a nonsignificant improvement in survival in the post-LAS era and equivalent late outcomes ( Figure 4B ; 68% versus 70% at 2 years, respectively; P=0.12).
Time-Varying Cox Proportional Hazards Analysis of Survival From Time of Listing
Univariate and multivariable time-varying Cox proportional hazards analyses of predictors of survival from the time of listing are shown in Table 3 . On multivariable analysis, being listed at a medium-or high-volume institution, having a higher cardiac index, having an improved forced vital capacity, undergoing DLT, and undergoing HLT all predicted survival, whereas male sex, worse functional status (New York Heart Association class IV), requiring life support, creatinine clearance <50 mL/min, and being listed for HLT predicted mortality (Table 3) . Notably, HLT (hazard ratio, 0.33; 95% confidence interval, 0.22-0.50, P<0.001) and DLT (hazard ratio, 0.82; 95% confidence interval, 0.67-0.99, P=0.05) were both independently associated with improved outcomes.
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increased donor age all predicted posttransplantation mortality (Table 2) . Notably, in our multivariable analysis, undergoing transplantation at a medium-or high-volume institution and receiving a transplant in the post-LAS era both approached but did not achieve significance as predictors of survival (hazard ratio, 0.80; 95% confidence interval, 0.60-1.08, P=0.14; and hazard ratio, 0.83; 95% confidence interval, 0.62-1.09, P=0.18, respectively).
Discussion
The present study examined wait-list and posttransplantation outcomes in patients with IPAH who were listed for LUT and HLT in the pre-and post-LAS eras. We found that the cumulative incidence of transplantation was improved whereas wait-list mortality was reduced for both LUT-and HLT-listed IPAH patients in the post-LAS era. Also, posttransplantation outcomes were improved in IPAH patients who underwent DLT (but not those who underwent HLT) in the post-LAS era. We identified multiple predictors of mortality from the time of wait-listing, including male sex, worse functional status, life support requirement, creatinine clearance <50 mL/min, and being listed for HLT. Furthermore, we identified multiple predictors of survival, including a higher cardiac index, being listed at a medium-or high-volume institution, an improved forced vital capacity, undergoing DLT, and undergoing HLT. Finally, among IPAH patients who received transplants, male sex, life support requirement at time of transplantation, and increased donor age predicted mortality, whereas a donor/ recipient sex match predicted improved survival. 
Wait-List Outcomes in the Pre-LAS and Post-LAS Eras
The severity of illness in IPAH patients listed for transplantation is emphasized when their outcomes are compared with those of IPAH patients from the REVEAL registry: The cumulative incidence of death among wait-listed IPAH patients was 2 to 4 times the 7% 1-year mortality rate in REVEAL patients. 6 Auspiciously, in both unmatched and matched comparisons, IPAH patients listed for LUT and HLT enjoyed improved wait-list outcomes in the post-LAS era. These improved outcomes probably result from the LAS matching algorithm that prioritizes sicker patients for transplantation, thereby increasing the incidence of early transplantation in patients who would have died on the wait list in the pre-LAS accumulated-time algorithm. Lending credence to this idea is the dramatic rise (near doubling) of the incidence of LUT and HLT in post-LAS era wait-listed patients.
Posttransplantation Survival in the Pre-LAS and Post-LAS Eras
Despite their worse comorbidities, post-LAS era patients who underwent DLT had improved early posttransplantation outcomes. These findings are surprising: if anything, one would expect posttransplantation outcomes to be worse in the post-LAS era given the algorithm's predilection for transplantation for sicker patients. These results may reflect advances in patient selection, operative technique, postoperative care, and the long-term surveillance of DLT recipients. Although a trend toward improved early outcomes was noted, posttransplantation survival in HLT recipients did not improve in the post-LAS era, even after propensity matching; the low number of patients who underwent HLT probably makes our analysis underpowered to detect such an improvement.
Predictors of Outcomes at Time of Listing and Time of Transplantation
Both DLT and HLT were associated with a significant reduction in patient mortality from the time of listing in our multivariable model, which suggests their utility in treating medically refractory IPAH. Our model also associated listing at a medium-to high-volume institution with improved outcomes; although higher transplantation volumes have previously been correlated with improved outcomes for LUT recipients, our finding that survival among wait-listed LUT and HLT candidates is improved at medium-to high-volume listing centers is novel. 36, 37 It suggests that patients listed at low-volume institutions may not receive more progressive treatments for IPAH before transplantation, or they may be inappropriately listed or withheld from listing for transplantation. Patients listed for HLT appear to have higher wait-list mortality than patients listed for LUT; the variables available in the UNOS data set could not explain this finding in the present multivariable analysis. Others have shown that right atrial pressure (a measure of right-sided heart dysfunction; not available in the UNOS data set) predicts worse outcomes in IPAH, which may account in part for the poor wait-list outcomes among HLT-listed patients. 19, 38, 39 Although our survival analysis revealed improved outcomes for LUT-and HLT-listed patients in the post-LAS era, our multivariable model did not find listing in the post-LAS era to significantly predict survival from the time of listing. This may be because listing in the post-LAS era is essentially a surrogate for speed to transplantation: The incidence of transplantation in wait-listed patients doubled between the pre-and post-LAS eras. Our analysis using the time-varying covariates of SLT, DLT, and HLT accounted for time to transplantation and thus removed the surrogate effect of increased transplantation rate from the post-LAS era variable. To confirm this, we repeated our Cox analysis without our time-varying variables and found that indeed, post-LAS era significantly predicted wait-list outcomes. Undergoing transplantation in the post-LAS era predicted (albeit nonsignificantly) improved posttransplantation survival; this finding supports our Kaplan-Meier survival data described above and shows that even though sicker patients are prioritized in the post-LAS era, posttransplantation outcomes in IPAH patients are not worse.
We found that higher cardiac index independently predicts improved survival in IPAH patients, which previous studies have also shown; together, these results argue for the inclusion of cardiac index in the LAS calculation for IPAH patients. 19, 39 Also, similar to studies of medically treated IPAH patients, the present study showed that male sex independently predicted worse outcomes; interestingly, this relationship appears to persist even after transplantation. 39, 40 Male sex has been associated with worse right ventricular function in IPAH patients, and right ventricular hypertrophy has been associated with heart failure and death, which suggests one possible explanation for male IPAH patients' worse outcomes. 41, 42 Sex and race matching have been shown to improve posttransplantation outcomes in heart transplant and LUT recipients, respectively; the present findings suggest that the benefit of donor/recipient sex matching (but not necessarily race matching) extends to IPAH patients. 43, 44 
Listing IPAH Patients for Transplantation
With the LAS allocation algorithm, patients are no longer listed for transplantation early in their disease course to accrue time on the waiting list; instead, their condition dictates the timing of transplantation. Previous findings suggest that the incidence of transplantation among wait-listed IPAH patients has increased substantially with this new allocation scheme, which the present results confirm. 19, 45 We believe this dramatic increase has occurred because organs are now being offered to sicker patients, who are likely to accept an available organ because of the severity of their condition. Nevertheless, other investigators have shown that compared with wait-listed LUT candidates with other conditions, wait-listed IPAH patients still have a lower incidence of transplantation and a higher mortality rate in the post-LAS era. 19 The present findings agreed with these: IPAH patients accounted for 8.1% of pre-LAS LUT or HLT candidates but only 4.8% of post-LAS candidates. In addition, of the pre-LAS era LUT and HLT recipients, 4.1% had IPAH as their diagnosis compared with only 3.0% of post-LAS era recipients. Thus, although the proportion of wait-listed IPAH patients who underwent transplantation increased substantially, IPAH patients represented a smaller percentage of all organ recipients in the post-LAS era. Whether the LAS gives appropriate priority to IPAH patients remains controversial. 19 When to list IPAH patients for transplantation remains a complex question. When listed too early in their disease course, they benefit little from the survival advantages of transplantation; when listed too late, they die waiting for an organ. Perhaps even more complex is the decision whether to list IPAH patients for LUT or HLT. At present, our institution continues to use indicators of right-sided heart dysfunction-including elevated right atrial pressures, reduced right ventricular function on echocardiography or catheterization, evidence of severe tricuspid regurgitation, peripheral edema, ascites/hepatic congestion, hepatic dysfunction, and inotrope dependence-to determine whether a patient should be listed for HLT rather than DLT. Severe overt right-sided heart failure, ascites, and significant peripheral edema despite optimal medical therapy in the presence of these other factors would warrant strong consideration for HLT. Further complicating matters is the fact that HLT removes 2 organs from the transplant donor pool; thus, the net transplantation benefit of HLT must be weighed against the opportunity cost of transplanting a heart and a lung separately to 2 separate patients.
Study Limitations
Limitations of the present study include its retrospective nature, its susceptibility to selection bias, and the fact that complete data are not available for every patient in the UNOS database. We attempted to address these limitations by using multiple imputation to account for missing data, propensity matching to account for treatment-selection bias, and multivariable analysis to account for confounding variables. Nevertheless, unmeasured variables and the observational nature of the present study leave ample room for residual bias to confound our results. Furthermore, evaluating the benefits of LUT in wait-listed patients involves complex statistical methods, none of which allow for definitive conclusions; our findings of improved outcomes with DLT and HLT in wait-listed IPAH patients should thus be considered with appropriate circumspection. 46 Also, clinical predictors of choice of intervention (HLT versus LUT), such as right atrial pressure, right ventricular function, the presence of ascites/peripheral edema, and brain natriuretic peptide levels, are not captured in the UNOS database and certainly could contribute additional bias and affect clinical outcomes in ways that could not be accounted for in the present analyses. 40
Conclusions
Despite the tremendous improvements in outcomes with medical therapy, survival remains dismal in end-stage IPAH patients wait-listed for LUT and HLT. The incidence of transplantation has improved dramatically with the implementation of the LAS algorithm, whereas wait-list mortality has been reduced. The present data suggest that HLT and DLT remain viable and important therapeutic options that are associated with improved survival in patients with IPAH for whom the limits of medical management have been reached. Listing patients at a medium-or high-volume institution is associated with a survival advantage, probably because these patients receive progressive IPAH treatments while on the wait list. Cardiac index is an important predictor of survival, and its inclusion in the LAS for IPAH patients warrants consideration. The present findings also support the utility of sex matching between donor and recipient; sex matching should be a priority in IPAH patients with less acute disease. Studying the subset of REVEAL patients who were subsequently listed for transplantation would help identify factors important in determining the best time to list IPAH patients for HLT or DLT.
CLINICAL PERSPECTIVE
Although the outcomes of patients with idiopathic pulmonary arterial hypertension (IPAH) have been improved by novel therapies such as prostacyclin analogues, endothelin receptor antagonists, and phosphodiesterase inhibitors, a significant subset of IPAH patients go on to develop refractory pulmonary hypertension (despite optimal medical therapy) and are listed for lung or heart-lung transplantation. In these patients, wait-list survival remains dismal. The recent implementation of the lung allocation score algorithm represents a dramatic shift in organ allocation, potentially having a significant impact on outcomes (both wait-list and posttransplantation) in IPAH patients. Our study showed that since the lung allocation score was implemented, the incidence of transplantation for wait-listed IPAH patients has improved dramatically, whereas waitlist mortality has been reduced. Our data indicate that heart-lung and double-lung transplantation remain viable and important therapeutic options that are associated with improved survival in patients with IPAH for whom the limits of medical management have been reached. In addition, listing patients at a medium-or high-volume institution was associated with a survival advantage, probably because these patients are afforded progressive IPAH treatments while on the wait list. The utility of sex matching between donor and recipient is also supported by our findings, and sex matching should be a priority in patients with less acute disease. A study of the subset of patients in the REVEAL study (Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management) who went on to be listed for transplantation may help elucidate which factors are important in determining the best time at which to list IPAH patients for heart-lung or doublelung transplantation.
Supplemental Material
Supplemental LAS indicates lung allocation score; BMI, body mass index; NYHA, New York Heart Association; VAD, ventricular assist device; ECMO, extracorporeal membrane oxygenation; CI, cardiac index; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; CrCl, creatinine clearance. *P-value based on χ 2 or Student t-test analysis.
